Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
By Dennis Thompson HealthDay Reporter
THURSDAY, Oct. 24, 2024 -- Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.
People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking seven other diabetes drugs, researchers reported Oct. 24 in the journal Alzheimer’s & Dementia.
The results jibe with other studies that have found semaglutide might protect against dementia, said lead researcher Rong Xu, a biomedical informatics professor with Case Western Reserve School of Medicine, in Cleveland.
“This new study provides real-world evidence for its impact on Alzheimer’s disease, even though preclinical research has suggested that semaglutide may protect against neurodegeneration and neuroinflammation,” Xu said in a Case Western news release.
Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.
For the study, researchers analyzed three years of health records for nearly 1 million U.S. patients with type 2 diabetes.
They found that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s disease, compared to those taking seven other diabetes meds.
However, they warned that more research is needed to confirm this potential benefit.
“Our results indicate that further research into semaglutide’s use will need to be further investigated through randomized clinical trials so alternative drugs can be tested as potential treatment for this debilitating illness,” Xu said.
Sources
- Case Western Reserve University, news release, Oct. 24, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Hearing Aids Are a Boon To Social Life, Study Finds
THURSDAY, July 3, 2025 — Some folks won’t use hearing aids because they’re worried the devices will make them look old or get in the way of their social...
Brainstorming? Avoid The Internet, Study Says
WEDNESDAY, July 2, 2025 — Want to think outside the box? Avoid the internet, a new study says. Googling for new ideas can inhibit a group’s creativity during...
AI Can Help Determine A Person's Specific Form Of Dementia
TUESDAY, July 1, 2025 — A new AI tool can help doctors hone in on a patient’s particular type of dementia, including Alzheimer’s disease, a new study says. The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.